Quantum Cyber NV
quantum-cyber.aiWhat Do They Do?
Develops blood- and stool-based pancreatic cancer screening tests, sells genetic diagnostic kits to laboratories and patients, and has a stated focus on post-quantum cybersecurity.
10-K for FY2025, filed Mar 31, 2026Historically, we have developed and sold in-vitro diagnostic (“IVD”) tests for the early detection of cancer. In March 2025, we acquired a…View ↗
In February 2026, we appointed David Lazar to our board of directors, and in March 2026, we announced the appointment of Robert Liscouski…View ↗
In March 2025, the Company entered into an Agreement with Liquid Biosciences. Under the terms of the Agreement, the Company has the rights…View ↗
We are also in the early stages of developing PancAlert, a stool-based screening test aimed at detecting pancreatic cancer.View ↗
The Company sells its genetic diagnostic testing kits to both laboratory partners and directly to patients who are the end users of the…View ↗
How Do They Make Money?
Laboratory partners buy genetic diagnostic kits, with sales counted when kits are delivered; patient tests are counted after samples are returned and results are delivered. The company also earns instrument rental income, counted monthly over the rental period.
10-K for FY2025, filed Mar 31, 2026
$537.1K
-
10-K for FY2025, filed Mar 31, 2026
$537.1K ↗
Who Are Their Customers?
Sells diagnostic kits to laboratory partners and directly to patients who use them; patient samples are sent to the company’s diagnostic lab for testing and results.
10-K for FY2025, filed Mar 31, 2026The Company sells its genetic diagnostic testing kits to both laboratory partners and directly to patients who are the end users of the…View ↗
Do Revenues Turn Into Profits?
No. It lost $16.2M in FY2025.
10-K for FY2025, filed Mar 31, 2026
−$16.1MView ↗
10-K for FY2025, filed Mar 31, 2026
−$16.2MView ↗
10-K for FY2025, filed Mar 31, 2026
−$11MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$11MView ↗
- ▲ +217% (Loss)
- vs −$3.5M in Q2 FY2025
-
Jul 1, 2026
Agreed to acquire a metal-stamping business
The agreement covers substantially all assets used in Arcade Metal Stamping and is part of a move toward domestic defense manufacturing.
Sources
8-K, filed Jul 1, 2026
On June 26, 2026, Quantum Drones Corporation (“Quantum Drones”), a Nevada corporation and wholly-owned subsidiary of Quantum Cyber N.V.…View ↗
-
Jun 26, 2026
Replaced its independent auditor
The audit committee dismissed Reliant CPA and engaged Haskell & White LLP.
Sources
8-K, filed Jun 26, 2026
On June 22, 2026, the Audit Committee of the Board of Directors (the “Committee”) of Quantum Cyber N.V. (the “Company”) approved the…View ↗
-
Jun 15, 2026
Licensed quantum-antenna technology for defense drones
The exclusive license covers technology for antenna systems used in unmanned aircraft and drone platforms for defense and national security.
Sources
8-K, filed Jun 15, 2026
On June 11, 2026 (the “Effective Date”), the Company entered into an Intellectual Property License Agreement (the “License Agreement”) with…View ↗
Cancer screening focus narrows
The older report lists ColoAlert as a product and PancAlert as early research; the latest says colorectal development ended and the business would focus on pancreatic screening.
20-F for FY2022, filed Apr 7, 2023 10-K for FY2025, filed Mar 31, 2026
Cybersecurity enters the strategy
The older report describes a cancer-diagnostics business, while the latest adds post-quantum cybersecurity to its stated strategic focus alongside pancreatic cancer detection.
20-F for FY2022, filed Apr 7, 2023 10-K for FY2025, filed Mar 31, 2026We are a molecular genetic diagnostic company dedicated to commercializing our product portfolio in Europe, the United States and the rest…View ↗
In February 2026, we appointed David Lazar to our board of directors, and in March 2026, we announced the appointment of Robert Liscouski…View ↗
Loading...
